ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent.
Aged
Aged, 80 and over
Antibodies, Anti-Idiotypic
/ genetics
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ drug therapy
DNA-Binding Proteins
/ genetics
Endonucleases
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Male
Middle Aged
Platinum
/ administration & dosage
ERCC1
Non-small cell lung cancer
chemotherapy
platinum drug
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
03
03
2021
revised:
17
03
2021
accepted:
19
03
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
14
5
2021
Statut:
ppublish
Résumé
To predict the efficacy of platinum-containing chemotherapy, ERCC1 expression levels were investigated. Studies have shown changes in the performance of anti-ERCC1 antibodies; therefore, predicting chemotherapy efficacy by immunohistochemical assessment of ERCC1 is controversial. Twenty-eight patients who received platinum-containing chemotherapy and underwent computed tomography evaluation 6-9 weeks after therapy initiation were retrospectively identified. The tumor samples were evaluated in 2012 and 2018 using the latest anti-ERCC1 antibodies available at those times. In 2012, the ERCC1 H-score was significantly higher in patients with disease progression than in patients without disease progression (p=0.019). Although the same trend was shown in 2018, there were some inconsistent results between the 2012 and 2018 samples. Patients with tumors showing low ERCC1 expression had a better disease control rate on platinum-containing chemotherapy. However, since the performance of the antibody changed over time, standardized technology to evaluate ERCC1 expression is needed.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
To predict the efficacy of platinum-containing chemotherapy, ERCC1 expression levels were investigated. Studies have shown changes in the performance of anti-ERCC1 antibodies; therefore, predicting chemotherapy efficacy by immunohistochemical assessment of ERCC1 is controversial.
PATIENTS AND METHODS
METHODS
Twenty-eight patients who received platinum-containing chemotherapy and underwent computed tomography evaluation 6-9 weeks after therapy initiation were retrospectively identified. The tumor samples were evaluated in 2012 and 2018 using the latest anti-ERCC1 antibodies available at those times.
RESULTS
RESULTS
In 2012, the ERCC1 H-score was significantly higher in patients with disease progression than in patients without disease progression (p=0.019). Although the same trend was shown in 2018, there were some inconsistent results between the 2012 and 2018 samples.
CONCLUSION
CONCLUSIONS
Patients with tumors showing low ERCC1 expression had a better disease control rate on platinum-containing chemotherapy. However, since the performance of the antibody changed over time, standardized technology to evaluate ERCC1 expression is needed.
Identifiants
pubmed: 33952496
pii: 41/5/2653
doi: 10.21873/anticanres.15046
doi:
Substances chimiques
Antibodies, Anti-Idiotypic
0
Biomarkers, Tumor
0
DNA-Binding Proteins
0
Platinum
49DFR088MY
ERCC1 protein, human
EC 3.1.-
Endonucleases
EC 3.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2653-2660Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.